NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading JSPR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is in a volatile phase, with management focusing on achieving financial stability while facing high risks and a fragile earnings quality.
The market seems to have priced in a neutral outlook, reflecting the company's recent financial performance, which is in the top half of its industry. However, it is also factoring in the high risk associated with its current loss-making status.
Management is making progress toward financial stability, as indicated by improvements in operating and net income. However, the company's fragile earnings quality and the high probability of missing earnings targets present significant near-term risks.
The long-term thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as well as potential rate cuts by the Fed. If these factors turn favorable, they could provide a boost to JSPR's performance.
In the next 1 to 3 years, JSPR's trajectory will depend heavily on external market conditions and management's ability to stabilize operations. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Jasper received a notice for not meeting the $1.00 share price. This affects its listing status.
Confirms:Jasper has a plan to meet Nasdaq's listing rules.
Disproves:Jasper does not respond well. This could lead to a delisting.
Why it matters: Earnings results will show if the company is financially stable. Investors want to see growth in operating income.
Confirms:Operating income improves further, showing a smaller loss than -$10.9M from Q1.
Disproves:Operating income worsens or remains at -$10.9M or worse.
Why it matters: The company received a notice for not meeting the $1.00 stock price. This could affect its listing status.
Confirms:The stock price stays above $1.00 for 30 consecutive trading days.
Disproves:The stock price closes below $1.00 for another 30 consecutive trading days.
Why it matters: The company received a notice for not meeting the minimum bid price. Compliance is crucial for continued listing.
Confirms:The company announced it is back in line with Nasdaq listing rules.
Disproves:Nasdaq sent more notice about ongoing non-compliance.
Why it matters: The earnings report will show if Jasper is doing better or worse.
Confirms one read:Earnings show a big drop in losses from earlier quarters.
Confirms the other:Earnings report shows bigger losses or no change in financial health.
Why it matters: Compliance with Nasdaq listing rules is critical for the company's stock. A delisting could hurt investor confidence.
Confirms:The company confirms it meets the $1.00 bid price requirement.
Disproves:There may be a notice of delisting or not meeting compliance rules.
Why it matters: An FDA meeting could signal progress towards a Phase 3 study for KP-104. This is crucial for its development timeline.
Confirms:Announcement of an end-of-Phase 2 meeting with the FDA regarding KP-104.
Disproves:No announcement or delay in scheduling the FDA meeting.
Why it matters: Updates on the pre-BLA meeting will indicate how close briquilimab is to market approval for SCID. This is a key value driver.
Confirms:The company shared the next steps after the pre-BLA meeting for briquilimab.
Disproves:No updates or delays in the pre-BLA meeting process.
